Syndax to present 19 revumenib and axatilimab abstracts at ASH 2026, including frontline AML data – Syndax

Syndax Pharmaceuticals will present 19 abstracts at the 68th ASH Annual Meeting (12–15 December 2026). Fourteen cover revumenib (Revuforj), including seven oral presentations, and five cover axatilimab (Niktimvo).

Revuforj is the first menin inhibitor approved by the FDA. It is indicated for adults and children aged one year and older with relapsed or refractory acute myeloid leukaemia (AML) with a susceptible NPM1 mutation who have no satisfactory alternative treatment options. It is also indicated for relapsed or refractory acute leukaemia with a KMT2A translocation.

Frontline combinations

Updated results will be presented from three trials in newly diagnosed NPM1-mutated or KMT2A-rearranged AML:

• Beat AML (oral): the final analysis of revumenib with venetoclax and azacitidine.
• SAVE (oral): an all-oral combination of revumenib, venetoclax and decitabine/cedazuridine.
• SNDX-5613-0708 (poster): revumenib with intensive chemotherapy.

Syndax says these trials show high remission rates, measurable residual disease (MRD) negativity and encouraging survival.

Transplant and MRD

Oral presentations will cover patients who went on to stem cell transplant after revumenib monotherapy, as well as first results of revumenib as post-transplant maintenance. Another oral presentation, from the INTERCEPT platform trial, will cover revumenib as pre-emptive therapy for MRD or early relapse.

Real-world and other data

Posters include real-world outcomes from the multicentre ROAR study and a single-centre experience, effects on transfusion dependence, and a Phase 1b/2 study combining revumenib with JAK inhibitors in myelofibrosis. Two preclinical orals will look at differing responses to menin inhibitors and at resistance mechanisms.

Axatilimab in chronic GVHD

Five axatilimab abstracts include long-term efficacy and safety data from the pivotal Phase 2 AGAVE-201 trial in recurrent or refractory chronic graft-versus-host disease (GVHD). One is a subgroup analysis of patients who were not taking corticosteroids at baseline.

“We particularly look forward to the presentation of updated frontline data from the BEAT AML, SAVE, and 708 trials,” said Nick Botwood, MBBS, Syndax’s head of R&D and chief medical officer.

Seven revumenib abstracts have been selected for oral presentation, covering newly diagnosed AML, transplant and measurable residual disease.